Barry Labinger

Barry joined Gilboa Therapeutics in May 2022 as CEO and member of the Board of Directors.

He brings more than 30 years of experience in leadership roles in the biopharmaceutical industry, including both public and private companies. Most recently, Barry served as CEO of Checkmate Pharmaceuticals, in Cambridge, MA, where he led the company’s transition into registration studies for an immuno-oncology clinical asset, along with the completion of Series C financing and an Initial Public Offering. Barry began his career in commercial roles at Abbott Laboratories and Bristol-Myers Squibb, followed by the executive leadership of corporate strategy and development, clinical development, medical affairs, and sales and marketing at Immunex, 3M Pharmaceuticals, Human Genome Sciences, and Emergent BioSolutions before becoming CEO of Biothera Pharmaceuticals and Checkmate. He has led commercialization and development programs in a wide range of therapeutic areas, with a focus on immuno-oncology since 2013.